Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-v2-691b42f1",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "claude-sonnet-4",
  "action": "support",
  "content": "# Practical Feasibility Assessment: Synaptic Pruning Therapeutics\n\n## Hypothesis 1: Complement C1q Mimetic Decoy Therapy\n**Revised Confidence: 0.45**\n\n### Druggability Assessment\n**Target Class:** Protein-protein interaction (PPI) - historically challenging but increasingly tractable\n**Chemical Matter:** \n- **Large molecule approach:** Engineered proteins/peptides mimicking C1q globular heads (22 kDa each)\n- **Small molecule approach:** PPI inhibitors targeting C1q-CR3 interface (challenging given large interaction surface ~1,500 Ų)\n- **Best bet:** Antibody-based decoys or engineered protein fragments\n\n### Existing Tools/Clinical Candidates\n- **C5 inhibitors:** Eculizumab (Soliris), Ravulizumab (Ultomiris) - approved but target downstream\n- **C1 esterase inhibitors:** Berinert, Cinryze - approved for hereditary angioedema\n- **Research tools:** Anti-C1q antibodies (ANX005 - ANI Pharmaceuticals, Phase 2 for ALS)\n- **Closest analogue:** None directly targeting C1q-microglial interactions\n\n### Competitive Landscape\n- **Direct competitors:** None identified\n- **Indirect competitors:** \n  - Neurimmune's aducanumab pathway (failed)\n  - Annexon Biosciences (ANX005) - targeting C1q in neurodegeneration\n  - Complement therapeutics focused on AMD/PNH markets\n\n### Safety Concerns\n- **Immunocompromise risk:** C1q essential for immune complex clearance\n- **Autoimmune disease risk:** C1q deficiency → SLE-like syndrome\n- **Infection susceptibility:** Complement system critical for bacterial defense\n- **Immunogenicity:** Engineered proteins likely antigenic\n\n### Cost & Timeline\n- **Discovery-IND:** $15-25M, 4-5 years (protein engineering, PK/PD optimization)\n- **Phase I/II:** $30-50M, 3-4 years\n- **Major hurdle:** Demonstrating CNS penetration of large molecules\n- **Total to proof-of-concept:** $45-75M, 7-9 years\n\n**Verdict:** **Moderate feasibility** - technically challenging but validated biology\n\n---\n\n## Hypothesis 4: Purinergic P2Y12 Inverse Agonist Therapy\n**Revised Confidence: 0.58**\n\n### Druggability Assessment\n**Target Class:** GPCR - highly druggable\n**Chemical Matter:**\n- **Existing scaffolds:** Thienopyridines, non-thienopyridine P2Y12 antagonists\n- **Chemistry starting point:** Modify clopidogrel/ticagrelor analogs for inverse agonism\n- **CNS penetration:** Major challenge - need to optimize beyond current P2Y12 inhibitors\n\n### Existing Tools/Clinical Candidates\n**Approved P2Y12 antagonists:**\n- Clopidogrel (Plavix) - prodrug, limited CNS penetration\n- Ticagrelor (Brilinta) - reversible, better CNS penetration\n- Prasugrel (Effient) - irreversible, limited CNS penetration\n\n**Research compounds:**\n- **Cangrelor** (IV only) - reversible, research tool\n- **PSB-0739** - potent antagonist, research grade\n- **No known inverse agonists** in clinical development\n\n### Competitive Landscape\n- **Platelet market:** Saturated ($10B+ annually)\n- **CNS P2Y12 space:** Completely open\n- **Potential players:** AstraZeneca, Bristol Myers Squibb (existing P2Y12 expertise)\n- **Academic centers:** Strong P2Y12 research at University of Missouri, King's College London\n\n### Safety Concerns\n- **Bleeding risk:** Major concern if systemic exposure occurs\n- **CNS selectivity critical:** Need >100-fold selectivity vs peripheral P2Y12\n- **Microglial dysfunction:** Risk of impairing beneficial surveillance functions\n- **Drug-drug interactions:** P2Y12 inhibitors interact with anticoagulants\n\n### Cost & Timeline\n- **Discovery-IND:** $8-15M, 3-4 years (medicinal chemistry optimization for CNS penetration)\n- **Phase I:** $10-20M, 18 months (extensive bleeding/platelet function monitoring)\n- **Phase IIa:** $25-40M, 2-3 years\n- **Total to proof-of-concept:** $43-75M, 6-8 years\n\n**Verdict:** **High feasibility** - excellent target class, clear medicinal chemistry path\n\n---\n\n## Hypothesis 2: Fractalkine Axis Amplification via CX3CR1 PAMs\n**Revised Confidence: 0.52**\n\n### Druggability Assessment\n**Target Class:** GPCR - highly druggable\n**Chemical Matter:**\n- **PAM chemistry:** Limited precedent for chemokine receptor PAMs\n- **Starting scaffolds:** CX3CR1 antagonist chemotypes could be modified\n- **Allosteric sites:** Poorly defined - would require extensive structure-based drug design\n\n### Existing Tools/Clinical Candidates\n**CX3CR1 antagonists (could inform PAM design):**\n- **AZD8797** (AstraZeneca) - Phase II for COPD (discontinued)\n- **GSK163090** (GSK) - preclinical\n- **Research tools:** Various academic compounds with limited drug-likeness\n\n**CX3CR1 PAMs:** None known in development or research\n\n### Competitive Landscape\n- **Chemokine receptor space:** Historically challenging (many failures)\n- **CX3CR1 specifically:** No active clinical programs identified\n- **Fractalkine therapeutics:** Recombinant CX3CL1 investigated briefly, abandoned\n\n### Safety Concerns\n- **Unknown PAM effects:** No precedent for CX3CR1 positive allosteric modulation\n- **Immune system effects:** CX3CR1 expressed on NK cells, T cells, monocytes\n- **Potential for receptor desensitization:** Risk with chronic GPCR activation\n\n### Cost & Timeline\n- **Discovery-IND:** $12-20M, 4-5 years (novel PAM discovery, extensive optimization)\n- **High failure risk:** 70%+ given limited precedent\n- **Phase I/IIa:** $30-45M, 3-4 years\n- **Total to proof-of-concept:** $42-65M, 7-9 years\n\n**Verdict:** **Moderate-low feasibility** - druggable target but high technical risk\n\n---\n\n## Hypothesis 6: Metabolic Reprogramming via Microglial Glycolysis Inhibition\n**Revised Confidence: 0.48**\n\n### Druggability Assessment\n**Target Class:** Metabolic enzymes - well-established druggability\n**Chemical Matter:**\n- **HK2 inhibitors:** 2-Deoxy-D-glucose, 3-bromopyruvate, lonidamine analogs\n- **PFKFB3 inhibitors:** 3PO, PFK15, AZ26 (research compounds)\n- **Brain penetration:** 2-DG crosses BBB but lacks selectivity\n\n### Existing Tools/Clinical Candidates\n**Glycolysis inhibitors in oncology:**\n- **2-Deoxy-D-glucose:** Phase I/II trials in cancer (limited efficacy)\n- **Lonidamine:** Phase III trials (mixed results, discontinued)\n- **3-Bromopyruvate:** Preclinical only (toxicity concerns)\n\n**CNS-specific approaches:** None in clinical development\n\n### Competitive Landscape\n- **Cancer metabolism:** Crowded field with multiple failures\n- **CNS metabolism:** Open field but high technical barriers\n- **Platform technologies:** Companies like Agios, Rafael Pharmaceuticals have relevant expertise\n\n### Safety Concerns\n- **Glucose homeostasis:** Risk of hypoglycemia\n- **Neuronal toxicity:** Neurons also use glycolysis, especially during stress\n- **Systemic effects:** Difficult to achieve brain selectivity\n- **Seizure risk:** 2-DG can cause seizures at high doses\n\n### Cost & Timeline\n- **Discovery-IND:** $10-18M, 3-4 years (CNS-selective delivery systems)\n- **Major technical hurdle:** Achieving microglial selectivity\n- **Phase I:** $15-25M, 2 years (extensive safety monitoring)\n- **Total to proof-of-concept:** $35-60M, 6-8 years\n\n**Verdict:** **Low-moderate feasibility** - established targets but selectivity challenges\n\n---\n\n## Hypothesis 3: TREM2 Conformational Stabilizers\n**Revised Confidence: 0.35**\n\n### Druggability Assessment\n**Target Class:** Immunoglobulin superfamily receptor - challenging\n**Chemical Matter:**\n- **Conformational stabilizers:** Very limited precedent\n- **Allosteric modulators:** Few successful examples for Ig-family receptors\n- **Likely approach:** Antibody-based or protein therapeutics\n\n### Existing Tools/Clinical Candidates\n**TREM2 agonists:**\n- **AL002** (Alector) - TREM2 agonist antibody, Phase I for AD\n- **Academic tools:** Various research antibodies, limited characterization\n\n**TREM2 modulators:** Very limited pipeline\n\n### Competitive Landscape\n- **TREM2 space:** Alector is the clear leader\n- **Microglial targets:** Crowded with many approaches\n- **Technical risk:** Extremely high given limited mechanistic understanding\n\n### Safety Concerns\n- **Unknown effects:** No precedent for conformational stabilization approach\n- **TREM2 loss-of-function is pathogenic:** Risk of inadvertent inhibition\n- **Immunogenicity:** Likely if protein-based approach\n\n### Cost & Timeline\n- **Discovery-IND:** $20-35M, 5-7 years (high technical risk)\n- **Failure probability:** 85%+ given limited precedent\n- **Total investment at risk:** $50-100M+\n\n**Verdict:** **Low feasibility** - technically very challenging, limited validation\n\n---\n\n## Hypothesis 7: Optogenetic Microglial Deactivation\n**Revised Confidence: 0.25**\n\n### Druggability Assessment\n**Target Class:** Optogenetics - not a drug target per se\n**Approach:** Gene therapy + implantable device\n- **Viral vectors:** AAV, lentivirus for opsin delivery\n- **Light delivery:** Implanted LED arrays or fiber optics\n- **Regulatory path:** Combination product (gene therapy + device)\n\n### Existing Tools/Clinical Candidates\n**Optogenetic clinical trials:**\n- **RST-001** (Allergan/RetroSense) - retinal optogenetics, Phase I/II\n- **PIONEER** (GenSight) - retinal optogenetics, Phase III\n- **No CNS optogenetic trials** for neurodegenerative diseases\n\n### Competitive Landscape\n- **Gene therapy space:** Crowded, high regulatory burden\n- **Neurotechnology:** Companies like Neuralink, Synchron in adjacent spaces\n- **Academic interest:** Strong but minimal commercial development\n\n### Safety Concerns\n- **Surgical risk:** Brain implantation procedures\n- **Long-term device complications:** Infection, hardware failure\n- **Immune response:** To viral vectors and opsin proteins\n- **Unknown long-term effects:** Of chronic microglial suppression\n\n### Cost & Timeline\n- **Preclinical development:** $25-40M, 4-6 years\n- **Regulatory approval:** Extremely complex (FDA combination product pathway)\n- **Clinical trials:** $75-150M, 8-12 years\n- **Total to market:** $150-300M+, 12-18 years\n\n**Verdict:** **Very low feasibility** - massive regulatory and commercial barriers\n\n---\n\n## Overall Recommendations\n\n### Most Promising (Worth Investment):\n1. **P2Y12 Inverse Agonists** - Clear medicinal chemistry path, druggable target\n2. **C1q Mimetic Decoys** - Strong biology despite technical challenges\n\n### Moderate Potential (Requires More Validation):\n3. **CX3CR1 PAMs** - Good target class but novel mechanism needs validation\n4. **Glycolysis Inhibitors** - Established chemistry but selectivity challenges\n\n### High Risk/Low Priority:\n5. **TREM2 Conformational Stabilizers** - Technically very challenging\n6. **Optogenetic Approaches** - Clinical translation barriers too high\n\n### Key Success Factors:\n- **CNS penetration:** Critical for all approaches\n- **Selectivity:** Must avoid systemic immune suppression\n- **Biomarkers:** Need to measure target engagement and synaptic preservation\n- **Patient stratification:** May need to focus on early-stage AD patients\n\n**Total sector investment needed:** $200-400M over 10-15 years across multiple approaches to have reasonable probability of clinical success.",
  "tokens_used": "2726"
}